1alpha,25-Dihydroxyvitamin D(3)-26,23-lactam Analogues Function As Vitamin D Receptor Antagonists in Human and Rodent Cells

Overview

Journal J Steroid Biochem Mol Biol

Specialties Biochemistry
Molecular Biology

Date 2008 May 27

PMID 18501591

Citations 4

Authors

Seiichi Ishizuka

Noriyoshi Kurihara

Yuko Hiruma

Daishiro Miura

Jun-ichi Namekawa

Azusa Tamura

Yuko Kato-Nakamura

Yusuke Nakano

Kazuya Takenouchi

Yuichi Hashimoto

Kazuo Nagasawa

G David Roodman

Affiliations

Soon will be listed here.

Abstract

(23S,25S)-N-Benzyl-1alpha,25-dihydroxyvitamin D(3)-26,23-lactam ((23S,25S)-N-benzyl-1alpha,25-(OH)(2)D(3)-26,23-lactam, (23S,25S)-DLAM-1P) antagonizes nuclear vitamin D receptor (VDR)-mediated differentiation of human promyelocytic leukemia (HL-60) cells [Y. Kato, Y. Nakano, H. Sano, A. Tanatani, H. Kobayashi, R. Shimazawa, H. Koshino, Y. Hashimoto, K. Nagasawa, Synthesis of 1alpha,25-dihydroxy vitamin D(3)-26,23-lactams (DLAMs), a novel series of 1alpha,25-dihydroxy vitamin D(3) antagonist, Bioorg. Med. Chem. Lett. 14 (2004) 2579-2583]. To enhance its VDR antagonistic actions, we synthesized multiple analogues of 1alpha,25-(OH)(2)D(3)-26,23-lactam. Among these analogues, (23S,25S)-N-phenetyl-1alpha,25-(OH)(2)D(3)-26,23-lactam, ((23S,25S)-DLAM-2P) had the strongest VDR binding affinity, which was 3 times higher than that of (23S,25S)-DLAM-1P. The 1alpha,25-(OH)(2)D(3)-26,23-lactam analogues never induced HL-60 cell differentiation even at 10(-6)M, but (23S,25S)-DLAM-1P and (23S,25S)-DLAM-2P significantly and dose-dependently inhibited HL-60 differentiation induced by 10(-8)M 1alpha,25-dihydroxyvitamin D(3) (1alpha,25-(OH)(2)D(3)). These compounds also inhibited human and mouse cultures of osteoclast formation by marrow cells treated with 1alpha,25-(OH)(2)D(3). Moreover, the 1alpha,25-(OH)(2)D(3)-26,23-lactam analogues minimally induced 25-hydroxyvitamin D(3)-24-hydroxylase gene expression in HL-60 cells and human and mouse osteoblastic cells, but 10(-6)M (23S,25S)-DLAM-1P or (23S,25S)-DLAM-2P significantly blocked 24-hydroxylase gene expression induced by 10(-8)M 1alpha,25-(OH)(2)D(3). (23S,25S)-DLAM-2P was 5-12 times more potent as a vitamin D antagonist than (23S,25S)-DLAM-1P in HL-60 cells, human and mouse bone marrow cultures. These results demonstrate that (23S,25S)-DLAM-1P and (23S,25S)-DLAM-2P antagonize HL-60 cell differentiation and osteoclast formation by human and mouse osteoclast precursors induced by 1alpha,25-(OH)(2)D(3) through blocking VDR-mediated gene transcription. In contrast, (23S)-25-deoxy-1alpha-hydroxyvitamin D(3)-26,23-lactone, which only blocks human VDR, these vitamin D antagonists can block VDR in human cells and rodent cells.

Citing Articles

Role of Vitamin D in Cognitive Dysfunction: New Molecular Concepts and Discrepancies between Animal and Human Findings.

Gall Z, Szekely O Nutrients. 2021; 13(11).

PMID: 34835929 PMC: 8620681. DOI: 10.3390/nu13113672.

Inhibitors for the Vitamin D Receptor-Coregulator Interaction.

Teske K, Yu O, Arnold L Vitam Horm. 2016; 100:45-82.

PMID: 26827948 PMC: 4740976. DOI: 10.1016/bs.vh.2015.10.002.

Vitamin D represses dentin matrix protein 1 in cementoblasts and osteocytes.

Nociti Jr F, Foster B, Tran A, Dunn D, Presland R, Wang L J Dent Res. 2013; 93(2):148-54.

PMID: 24334408 PMC: 6728571. DOI: 10.1177/0022034513516344.

Vitamin D3-driven signals for myeloid cell differentiation--implications for differentiation therapy.

Hughes P, Marcinkowska E, Gocek E, Studzinski G, Brown G Leuk Res. 2009; 34(5):553-65.

PMID: 19811822 PMC: 2847023. DOI: 10.1016/j.leukres.2009.09.010.

References

Ozono K, Saito M, Miura D, Michigami T, Nakajima S, Ishizuka S . Analysis of the molecular mechanism for the antagonistic action of a novel 1alpha,25-dihydroxyvitamin D(3) analogue toward vitamin D receptor function. J Biol Chem. 1999; 274(45):32376-81. DOI: 10.1074/jbc.274.45.32376. View

Ochiai E, Miura D, Eguchi H, Ohara S, Takenouchi K, Azuma Y . Molecular mechanism of the vitamin D antagonistic actions of (23S)-25-dehydro-1alpha-hydroxyvitamin D3-26,23-lactone depends on the primary structure of the carboxyl-terminal region of the vitamin d receptor. Mol Endocrinol. 2005; 19(5):1147-57. DOI: 10.1210/me.2004-0234. View

Kurihara N, Reddy S, Araki N, Ishizuka S, Ozono K, Cornish J . Role of TAFII-17, a VDR binding protein, in the increased osteoclast formation in Paget's Disease. J Bone Miner Res. 2004; 19(7):1154-64. DOI: 10.1359/JBMR.040312. View

Vaisanen S, Perakyla M, Karkkainen J, Steinmeyer A, Carlberg C . Critical role of helix 12 of the vitamin D(3) receptor for the partial agonism of carboxylic ester antagonists. J Mol Biol. 2002; 315(2):229-38. DOI: 10.1006/jmbi.2001.5225. View

Kukita A, Chenu C, McManus L, Mundy G, Roodman G . Atypical multinucleated cells form in long-term marrow cultures from patients with Paget's disease. J Clin Invest. 1990; 85(4):1280-6. PMC: 296564. DOI: 10.1172/JCI114565. View

Bury Y, Steinmeyer A, Carlberg C . Structure activity relationship of carboxylic ester antagonists of the vitamin D(3) receptor. Mol Pharmacol. 2000; 58(5):1067-74. DOI: 10.1124/mol.58.5.1067. View

Kato Y, Nakano Y, Sano H, Tanatani A, Kobayashi H, Shimazawa R . Synthesis of 1alpha,25-dihydroxyvitamin D3-26,23-lactams (DLAMs), a novel series of 1 alpha,25-dihydroxyvitamin D3 antagonist. Bioorg Med Chem Lett. 2004; 14(10):2579-83. DOI: 10.1016/j.bmcl.2004.02.076. View

Norman A, Bouillon R, Farach-Carson M, Bishop J, Zhou L, Nemere I . Demonstration that 1 beta,25-dihydroxyvitamin D3 is an antagonist of the nongenomic but not genomic biological responses and biological profile of the three A-ring diastereomers of 1 alpha,25-dihydroxyvitamin D3. J Biol Chem. 1993; 268(27):20022-30. View

Ishizuka S, Oshida J, Tsuruta H, Norman A . The stereochemical configuration of the natural 1 alpha,25-dihydroxyvitamin D3-26,23-lactone. Arch Biochem Biophys. 1985; 242(1):82-9. DOI: 10.1016/0003-9861(85)90482-5. View

10.

Ishizuka S, Kurihara N, Reddy S, Cornish J, Cundy T, Roodman G . (23S)-25-Dehydro-1{alpha}-hydroxyvitamin D3-26,23-lactone, a vitamin D receptor antagonist that inhibits osteoclast formation and bone resorption in bone marrow cultures from patients with Paget's disease. Endocrinology. 2004; 146(4):2023-30. DOI: 10.1210/en.2004-1140. View

11.

Ishizuka S, Sumitani K, Hiura K, Kawata T, Okawa M, Hakeda Y . Biological activity assessment of 1 alpha,25-dihydroxyvitamin D3-26,23-lactone and its intermediate metabolites in vivo and in vitro. Endocrinology. 1990; 127(2):695-701. DOI: 10.1210/endo-127-2-695. View

12.

Collins S, Ruscetti F, Gallagher R, Gallo R . Normal functional characteristics of cultured human promyelocytic leukemia cells (HL-60) after induction of differentiation by dimethylsulfoxide. J Exp Med. 1979; 149(4):969-74. PMC: 2184853. DOI: 10.1084/jem.149.4.969. View

13.

Miura D, Manabe K, Gao Q, Norman A, Ishizuka S . 1alpha,25-dihydroxyvitamin D(3)-26,23-lactone analogs antagonize differentiation of human leukemia cells (HL-60 cells) but not of human acute promyelocytic leukemia cells (NB4 cells). FEBS Lett. 1999; 460(2):297-302. DOI: 10.1016/s0014-5793(99)01347-2. View

14.

Herdick M, Steinmeyer A, Carlberg C . Antagonistic action of a 25-carboxylic ester analogue of 1alpha, 25-dihydroxyvitamin D3 is mediated by a lack of ligand-induced vitamin D receptor interaction with coactivators. J Biol Chem. 2000; 275(22):16506-12. DOI: 10.1074/jbc.M910000199. View

15.

Menaa C, BARSONY J, Reddy S, Cornish J, Cundy T, Roodman G . 1,25-Dihydroxyvitamin D3 hypersensitivity of osteoclast precursors from patients with Paget's disease. J Bone Miner Res. 2000; 15(2):228-36. DOI: 10.1359/jbmr.2000.15.2.228. View

16.

Ishizuka S, Miura D, Eguchi H, Ozono K, Chokki M, Kamimura T . Antagonistic action of novel 1alpha,25-dihydroxyvitamin D(3)-26, 23-lactone analogs on 25-hydroxyvitamin-D(3)-24-hydroxylase gene expression induced by 1alpha,25-dihydroxy-vitamin D(3) in human promyelocytic leukemia (HL-60) cells. Arch Biochem Biophys. 2000; 380(1):92-102. DOI: 10.1006/abbi.2000.1902. View

17.

Kurihara N, Reddy S, Menaa C, Anderson D, Roodman G . Osteoclasts expressing the measles virus nucleocapsid gene display a pagetic phenotype. J Clin Invest. 2000; 105(5):607-14. PMC: 289182. DOI: 10.1172/JCI8489. View

18.

Ishizuka S, Bannai K, Naruchi T, Hashimoto Y . Studies on the mechanism of action of 1 alpha, 24-dihydroxyvitamin D3. II. Specific binding of alpha, 24-dihydroxyvitamin D3 to chick intestinal receptor. Steroids. 1981; 37(1):33-43. DOI: 10.1016/0039-128x(81)90005-2. View

19.

Carlberg C . Ligand-mediated conformational changes of the VDR are required for gene transactivation. J Steroid Biochem Mol Biol. 2004; 89-90(1-5):227-32. DOI: 10.1016/j.jsbmb.2004.03.112. View

20.

Bhatia M, Kirkland J . Monocytic differentiation of acute promyelocytic leukemia cells in response to 1,25-dihydroxyvitamin D3 is independent of nuclear receptor binding. J Biol Chem. 1995; 270(27):15962-5. DOI: 10.1074/jbc.270.27.15962. View